Paul J. Diaz
Net Worth

Last updated:

What is Paul J. Diaz net worth?

The estimated net worth of Mr. Paul J. Diaz is at least $13,832,579 as of 11 Oct 2024. He owns shares worth $5,369,107 as insider, has earned $6,473,472 from insider trading and has received compensation worth at least $1,990,000 in Myriad Genetics, Inc..

What is the salary of Paul J. Diaz?

Mr. Paul J. Diaz salary is $1,990,000 per year as Chief Executive Officer, Pres & Director in Myriad Genetics, Inc..

How old is Paul J. Diaz?

Mr. Paul J. Diaz is 63 years old, born in 1962.

What stocks does Paul J. Diaz currently own?

As insider, Mr. Paul J. Diaz owns shares in one company:

Company Title Shares Price per share Total value
Myriad Genetics, Inc. (MYGN) Chief Executive Officer, Pres & Director 962,378 $5.58 $5,369,107

What does Myriad Genetics, Inc. do?

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Paul J. Diaz insider trading

Myriad Genetics, Inc.

Mr. Paul J. Diaz has made 5 insider trades in 2024, according to the Form 4 filled with the SEC. Most recently he sold 15,000 units of MYGN stock worth $343,950 on 11 Oct 2024.

The largest trade he's ever made was exercising 95,000 units of MYGN stock on 14 May 2024. As of 11 Oct 2024 he still owns at least 962,378 units of MYGN stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 15,000 $22.93 $343,950
Sale
Common Stock 15,000 $26.72 $400,800
Sale
Common Stock 75,000 $25.07 $1,880,400
Sale
Common Stock 95,000 $25.21 $2,394,760
Sale
Common Stock 57,844 $25.13 $1,453,562

Myriad Genetics key executives

Myriad Genetics, Inc. executives and other stock owners filed with the SEC: